Filing Flows › Agios Pharmaceuticals (AGIO) › Q3 2026 › vs Q3 2025
Agios Pharmaceuticals (AGIO) Q3 2026 vs Q3 2025 (year over year)
Agios Pharmaceuticals's revenue rose $42.5M (+330%) from $12.9M in Q3 2025 to $55.4M in Q3 2026.
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $55.4M | $12.9M | $42.5M | +330% |
| Other income, net | $12.1M | $13.4M | −$1.3M | -10% |
| Net loss | $65.0M | $103M | −$38.4M | -37% |
| Costs & expenses | $133M | $130M | $2.8M | +2% |
| Operating costs | $133M | $130M | $2.8M | +2% |
| Cost of revenue | $2.5M | $1.7M | $846K | +50% |
| Research & development | $73.5M | $86.8M | −$13.3M | -15% |
| SG&A | $56.5M | $41.3M | $15.3M | +37% |
| Operating cash sources | $75.9M | $101M | −$24.6M | -24% |
| Share-based compensation | $16.7M | $12.4M | $4.3M | +35% |
| Cash used in operations | $59.2M | $88.2M | −$28.9M | -33% |
| Net loss absorbed | $65.0M | $103M | −$38.4M | -37% |
| Working capital & other | $10.9M | −$2.9M | $13.8M | — |
Questions
How much did Agios Pharmaceuticals's revenue grow year over year in Q3 2026?
Agios Pharmaceuticals's revenue rose $42.5M (+330%) from $12.9M in Q3 2025 to $55.4M in Q3 2026.